Insulin glargine use and breast cancer
A systematic review and meta-analysis
Keywords:
Insulin glargine, Dose, and duration, Breast cancerAbstract
Abstract Background: Insulin is widely used in the treatment of diabetes. There is an increasing concern regarding the association between insulin glargine use and breast cancer. Aim: To systematically review the literature on insulin glargine use and breast cancer risk. Methods: A systematic literature search on the relevant articles assessing insulin glargine use and breast cancer during the period from January 2008 to January 2018 was carried out. Studies on animals, human cell line, and humans, in English language that state the duration and dose of insulin glargine use, and the number of participants were retrieved from MEDLINE, Web Of Science, EMBASE, PubMed, and EBSCO, using the keywords insulin glargine, insulin Lantus, insulin analogs, breast neoplasia, and breast cancer. Results: Out of 311 articles, 34 manuscripts stand after duplication removal and applying the inclusion and exclusion criteria (twelve experimental studies, eight reviews, and fourteen human studies). The reviews’ results were inconclusive, human studies showed no relation of insulin glargine with breast cancer except at high dose and long duration of ≥ five years, and prior human insulin use, while the experimental studies showed a decreased breast cancer latency. Conclusion: There is no association between insulin glargine and breast cancer. Some of the studies showed an association with a long duration of high doses and prior human insulin use. Treating physicians may need to use insulin glargine as the basal insulin of choice before human insulin, although the dose and duration need to be taken into consideration. Real-world studies are needed.References
Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem
Biophys. 2015; 72(2): 333-8. doi: 10.1007/s12013-014-0459-6. PMID: 25543329.
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its
complications. Nat Rev Endocrinol. 2018; 14(2): 88-98. doi: 10.1038/nrendo.2017.151. PMID: 29219149.
Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescription, cost, and adherence
to treatment guidelines; A prospective, cross-sectional study at a tertiary care teaching hospital. J Basic
Clin Pharm. 2013; 4: 82-7. doi: 10.4103/0976-0105.121653. PMID: 24808678, PMCID: PMC3979268.
Martin SD, McGee SL. Metabolic reprogramming in type 2 diabetes and the development of breast cancer.
J Endocrinol. 2018; 237(2): 35-46. doi: 10.1530/JOE-18-0037. PMID: 29487204.
Lega IC, Austin PC, Fischer HD, Fung K, Krzyzanowska MK, Amir E, et al. The Impact of Diabetes on
Breast Cancer Treatments and Outcomes: A Population-Based Study. Diabetes Care. 2018; 41(4): 755-61.
doi: 10.2337/dc17-2012. PMID: 29351960.
Chang YL, Sheu WH, Lin SY, Liou WS. Good glycaemic control is associated with a better prognosis in
breast cancer patients with type 2 diabetes mellitus. Clin Exp Med. 2018; 18(3): 383-90. doi:
1007/s10238-018-0497-2. PMID: 29572669.
Parada H Jr, Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, et al. Genetic polymorphisms
of diabetes-related genes, their interaction with diabetes status, and breast cancer incidence and mortality:
The Long Island Breast Cancer Study Project. Mol Carcinog. 2019; 58(3): 436-46. doi: 10.1002/mc.22940.
PMID: 30457165.
Munshi MN, Gill J, Chao J, Nikonova EV, Patel M. insulin glargine 300 u/ml is associated with less weight
gain while Maintaining Glycemic Control and Low Risk of Hypoglycemia Compared with Insulin Glargine
U/ML in An Aging Population With Type 2 Dabetes. Endocr Pract. 2018; 24(2): 143-9. doi:
4158/EP171922.OR. PMID: 29106816.
Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, et al. Similar risk of malignancy with
insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings
from a 5 year randomised, open-label study. Diabetologia. 2009; 52: 1971–3. doi: 10.1007/s00125-009- 1452-2. PMID: 19609501, PMCID: PMC2723677.
Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses
(PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2011; 39(2): 91-2. doi:
1016/j.jcms.2010.11.001. PMID: 21145753.
Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on
the risk of breast cancer. Diabetologia. 2011; 54(9): 2254-62. doi: 10.1007/s00125-011-2190-9. PMID:
Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and
risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic
treatments in patients with diabetes. Prim Care Diabetes. 2012; 6(1): 53-9. doi: 10.1016/j.pcd.2011.10.004.
PMID: 22056422.
Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH et al. Risk of
cancer in patients on insulin glargine and other insulin analogues in comparison with those on human
insulin: results from a large population-based follow-up study. Diabetologia. 2012 Jan;55(1):51-62. doi:
1007/s00125-011-2312-4. PMID: 21956710 PMCID: PMC3228952
Wu JW, Filion KB, Azoulay L, Doll MK, Suissa S. Effect of Long-Acting Insulin Analogs on the Risk of
Cancer: A Systematic Review of Observational Studies. Diabetes Care. 2016; 39(3): 486-94. doi:
2337/dc15-1816, PMID: 26740633.
ter Braak B, Siezen C, Speksnijder EN, Koedoot E, van Steeg H, Salvatori DC, et al. Mammary gland
tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the
p53R270H/⁺WAPCre mouse model. Breast Cancer Res. 2015; 17: 14. doi: 10.1186/s13058-015-0518-y.
PMID: 25848982, PMCID: PMC4349771.
terBraak B, Wink S, Koedoot E, Pont C, Siezen C, van der Laan JW, et al. Alternative signaling network
activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin
analogues in human mammary epithelial cells. Breast Cancer Res. 2015; 17: 97. doi: 10.1186/s13058-015- 0600-5. PMID: 26187749, PMCID: PMC4506606.
Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells.
Arch Physiol Biochim. 2008; 114(1): 38-44. doi: 10.1080/13813450801900645. PMID: 18465357.
Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic
and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009; 25(1): 41-9. doi:
1002/dmrr.912. PMID: 19145584.
Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. Analysis of signaling pathways
related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr
Relat Cancer. 2009; 16(2): 429-41. doi: 10.1677/ERC-08-0240. PMID: 19153208.
terBraak B, Siezen CL, Kannegieter N, Koedoot E, van de Water B, van der Laan JW. Classifying the
adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically
engineered human breast cancer cell panel. Arch Toxicol. 2014; 88(4): 953-66. doi: 10.1007/s00204-014- 1201-2. PMID: 24464500.
Pierre-Eugene C, Pagesy P, Nguyen TT, Neuillé M, Tschank G, Tennagels N, et al. Effect of insulin
analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1
and M2. PLoS One. 2012; 7(7): e41992. doi: 10.1371/journal.pone.0041992. PMID: 22848683, PMCID:
PMC3406060.
Teng JA, Hou RL, Li DL, Yang RP, Qin J. Glargine promotes proliferation of breast adenocarcinoma cell
line MCF-7 via AKT activation. Horm Metab Res. 2011; 43(8): 519-23. doi: 10.1055/s-0031-1280780.
PMID: 21773964.
Rensing KL, Houttuijn Bloemendaal FM, Weijers EM, Richel DJ, Büller HR, Koolwijk P, et al. Could
recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local
angiogenesis? Diabetologia. 2010; 53(5): 966-70. doi: 10.1007/s00125-010-1687-y. PMID: 20182859,
PMCID: PMC2850513.
Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the
serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochim.
; 116(2): 73-8. doi: 10.3109/13813451003631439. PMID: 20199195.
Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using
insulin glargine. Diabetologia. 2009; 52(12): 2499-506. doi: 10.1007/s00125-009-1530-5. PMID:
, PMCID: PMC2776153.
Call R, Grimsley M, Cadwallader L, Cialone L, Hill M, Hreish V, et al. Insulin--carcinogen or mitogen?
Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad
Med. 2010; 122(3): 158-65. doi: 10.3810/pgm.2010.05.2153. PMID: 20463425.
Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
PLoS One. 2012; 7(12): e51814. doi: 10.1371/journal.pone.0051814. PMID: 23284776, PMCID:
PMC3526637.
Bronsveld HK, terBraak B, Karlstad Ø, Vestergaard P, Starup-Linde J, Bazelier MT, et al. Treatment with
insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro,
animal, and human evidence. Breast Cancer Res. 2015; 17: 100. doi: 10.1186/s13058-015-0611-2. PMID:
, PMCID: PMC4531810.
Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and
insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr
Drug Saf. 2013; 8(5): 333-48. PMID: 24215311, PMCID: PMC3899599.
Hernández-Díaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible
explanations. Diabetologia. 2010; 53(5): 802-8. doi: 10.1007/s00125-010-1675-2. PMID: 20177658.
Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship
between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.
Diabetes Care. 2011; 34(9): 1965-71. doi: 10.2337/dc11-0699. PMID: 21775752, PMCID: PMC3161263.
Fagot JP, Blotière PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of
cancer compared with other basal insulins? A French nationwide cohort study based on national
administrative databases. Diabetes Care. 2013; 36(2): 294-301. doi: 10.2337/dc12-0506. PMID: 22966091,
PMCID: PMC3554310.
Peeters PJ, Bazelier MT, Leufkens HG, Auvinen A, van Staa TP, de Vries F, et al. Insulin glargine use and
breast cancer risk: Associations with cumulative exposure. Acta Oncol. 2016; 55(7): 851-8. doi:
3109/0284186X.2016.1155736. PMID: 27150973, PMCID: PMC4975082.
Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, et al. Cohort study of
insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes
Care. 2013; 36(12): 3953-60. doi: 10.2337/dc13-0140. PMID: 24170756, PMCID: PMC3836110.
Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S. Long-Term Use of Long-Acting Insulin
Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. J ClinOncol. 2017; 35(32): 3647- 3653. doi: 10.1200/JCO.2017.73.4491. PMID: 28953430.
Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and
short-term incidence of malignancies - a three-year population-based observation. Acta Oncol. 2011; 50(5):
-93. doi: 10.3109/0284186X.2011.558913. PMID: 21506898.
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and
short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;
(9): 1745-54. doi: 10.1007/s00125-009-1444-2. PMID: 19588120.
SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the
Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; 52(9): 1755-65. doi:
1007/s00125-009-1453-1. PMID: 28512700
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2
diabetes. Diabetologia. 2009; 52(9): 1766-77. doi: 10.1007/s00125-009-1440-6. PMID: 19572116.
Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, et al. Risk of breast
cancer by individual insulin use: an international multicenter study. Diabetes Care. 2014; 37(1): 134-43.
doi: 10.2337/dc13-0695. PMID: 23949559.
Stürmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, et al. Cancer incidence among those
initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care. 2013; 36(11): 3517-25.
doi: 10.2337/dc13-0263. PMID: 23877991, PMCID: PMC3816915.
Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M. Cancer-specific mortality in insulin-treated type
diabetes patients. PLoS One. 2014; 9(3): e93132. doi: 10.1371/journal.pone.0093132. PMID: 24667573,
PMCID: PMC3965531.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
